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Background: Serotonin (5-HT3) receptor antagonists are commonly used to decrease nausea and vomiting for
surgery patients, but these agents may be harmful. We conducted a systematic review on the comparative safety of
5-HT3 receptor antagonists.
Methods: Searches were done in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to
identify studies comparing 5-HT3 receptor antagonists with each other, placebo, and/or other antiemetic agents for
patients undergoing surgical procedures. Screening search results, data abstraction, and risk of bias assessment were
conducted by two reviewers independently. Random-effects pairwise meta-analysis and network meta-analysis
(NMA) were conducted. PROSPERO registry number: CRD42013003564.
Results: Overall, 120 studies and 27,787 patients were included after screening of 7,608 citations and 1,014 full-text
articles. Significantly more patients receiving granisetron plus dexamethasone experienced an arrhythmia relative to
placebo (odds ratio (OR) 2.96, 95 % confidence interval (CI) 1.11–7.94), ondansetron (OR 3.23, 95 % CI 1.17–8.95),
dolasetron (OR 4.37, 95 % CI 1.51–12.62), tropisetron (OR 3.27, 95 % CI 1.02–10.43), and ondansetron plus dexamethasone
(OR 5.75, 95 % CI 1.71–19.34) in a NMA including 31 randomized clinical trials (RCTs) and 6,623 patients of all ages.
No statistically significant differences in delirium frequency were observed across all treatment comparisons in a NMA
including 18 RCTs and 3,652 patients.
Conclusion: Granisetron plus dexamethasone increases the risk of arrhythmia.
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Postoperative vomitingBackground
Serotonin (5-HT3) receptor antagonists are a class of anti-
emetics recommended for patients undergoing surgery
who are at risk for nausea and vomiting [1, 2]. Serotonin
(5-HT3) receptor antagonists reduce nausea and vomiting
by inhibiting vagal nerves in the central nervous system* Correspondence: sharon.straus@utoronto.ca
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creativecommons.org/publicdomain/zero/1.0/and intestinal mucosa [3]. However, some evidence sug-
gests that 5-HT3 receptor antagonists can increase the risk
of cardiac harm in children undergoing chemotherapy [4,
5]. Adverse events associated with these medications in-
clude a decrease in heart rate and prolongation of the QT
interval. We were commissioned by Health Canada, a
department of the federal government, to determine the
comparative safety of 5-HT3 receptor antagonists for pa-
tients of all ages undergoing surgery due to safety concerns
regarding the 5-HT3 receptor antagonists.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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We used an integrated knowledge translation approach
[6], entailing collaboration between researchers and re-
search users throughout the conduct of this study. The
research users involved in this study who posed the
original study question were from Health Canada.
Protocol
A protocol was developed and revised using feedback
from the research team and the research users. We regis-
tered our protocol with PROSPERO (CRD42013003564)
and published it in an open-access journal [7]. Our
methods are described briefly here; additional details can
be found in the protocol publication. We originally
intended to evaluate both safety and efficacy outcomes for
patients undergoing surgery or chemotherapy; however,
due to the enormous number of studies that met the in-
clusion criteria, we made slight changes to our protocol
and subdivided the analyses. The current paper focuses on
the safety of 5-HT3 antagonists in patients undergoing
surgery. Subsequent papers will examine the efficacy of
5-HT3 antagonists for patients undergoing surgery [8],
and the efficacy and safety of 5-HT3 antagonists for
patients undergoing chemotherapy.
Eligibility criteria
We included experimental (randomized clinical trials
(RCTs), quasi-RCTs, non-RCTs), quasi-experimental
(interrupted time series, controlled before–after studies),
and observational (cohort) studies involving patients
of any age undergoing any type of surgery who were given
a 5-HT3 receptor antagonist for nausea and/or vomiting.
A list of the agents and relevant comparators that were
investigated in the included studies can be found in
Additional file 1: Appendix 1. The primary outcome was
the number of patients experiencing arrhythmia, and sec-
ondary outcomes were QT prolongation, PR prolongation,
delirium, and mortality (overall and sudden cardiac death).
Given the large number of included studies we limited the
review to those published in English. Studies suspected or
identified as fraudulent were excluded [9].
Information sources
An experienced librarian executed searches of MED-
LINE, Embase, and the Cochrane Central Register of
Controlled Trials from inception until 11 January 2013.
Unpublished studies were sought by searching trial
protocol registries and conference proceedings.
Study selection and data collection
After a calibration exercise, the literature search results
were screened by pairs of reviewers, working independ-
ently. The same approach was used to abstract data and
appraise the quality of included studies. Conflicts at boththe screening and the abstraction steps were resolved
through discussion. When data was missing or clarification
of published data was needed we contacted the authors.
Appraisal of methodological quality and risk of bias
To assess methodological quality and risk of bias of the in-
cluded studies, we used the Cochrane Effective Practice
and Organisation of Care risk of bias tool for experimental
and quasi-experimental studies [10], the Newcastle-
Ottawa Scale [11] for cohort studies, and the McMaster
Quality Assessment Scale of Harms (known as the
McHarm tool) [12] for studies reporting harms.
Synthesis of included studies
A pooled estimate of effect was derived on the odds ratio
(OR) scale using random-effects pairwise meta-analysis for
each outcome and comparison, if at least two studies were
available. When studies reported zero events in one treat-
ment arm, 0.5 was added to the numerator and 1 was
added to the denominator. Studies with zero events in both
arms were excluded from the analyses. Between-study
heterogeneity for direct-comparison meta-analysis was esti-
mated using the restricted maximum likelihood (REML)
[13] and measured using the I2 statistic [14]. Each pairwise
meta-analysis estimate is presented along with the corre-
sponding 95% confidence interval (CI). These analyses were
conducted using the metafor package [15] in R 3.1.2 [16].
Before embarking on network meta-analysis (NMA),
we evaluated the transitivity assumption by examining
the comparability of the distributions of age (children
versus adults), timing of administration (all time points
versus during surgery), and risk of bias (all versus re-
moving high risk of bias for randomization, allocation
concealment, and blinding of outcome assessor) as po-
tential treatment-effect modifiers across comparisons
[17]. For each outcome, we visually inspected the poten-
tial effect modifiers by using colored edges in the net-
work according to the level of the effect modifier and
the majority of trials included in each comparison [18].
We evaluated the consistency assumption for the entire
network using the design-by-treatment interaction model
[19]. In case we found statistically significant inconsist-
ency, we planned to assess certain paths of the network
using the loop-specific method [20, 21] to identify which
piece of evidence was responsible for the inconsistency
(i.e., local inconsistency). We also planned to apply net-
work meta-regression to adjust for potential effect modi-
fiers if local inconsistency was identified. NMAs were
performed within a frequentist framework, assuming a
common within-network estimate for the heterogeneity
parameter across all comparisons and estimated with the
REML [13, 19]. We used the surface under the cumulative
ranking (SUCRA) curve to rank the safety of the various
5-HT3 receptor antagonists [22].
Tricco et al. BMC Medicine  (2015) 13:142 Page 3 of 13The treatment nodes were selected with input from cli-
nicians, pharmacists, and statisticians on the team. Due to
the complexity of the analysis, we did not account for dif-
ferences in doses and durations assuming that all impact
the treatment effect equally. Specifically, when a study
compared different doses of an intervention against an-
other intervention, we included only the recommended
dose in the analysis [1, 23–33].
The summary treatment effect generated by each
NMA is presented along with its 95 % CI and 95 % pre-
dictive interval (PrI). The PrI, representing the interval
within which the estimated treatment effect of a future
study is expected to lie, captures the uncertainty of the
NMA estimate and the magnitude of heterogeneity
within the network overall [34, 35]. To assess the pres-
ence of reporting bias (including publication bias and
small-study effects), we applied the comparison-adjusted
funnel plot for each outcome separately [18]. We or-
dered the treatments from oldest to newest and then
plotted the difference between each study-specific treat-
ment effect and the corresponding comparison-specific
summary effect under the fixed-effect model, against the
study-specific standard error. We carried out subgroup
analyses for all outcomes according to the timing ofFig. 1 Study flow. Details the flow of information through the different ph
included and excluded, and the reasons for their exclusionadministration of 5-HT3 receptor antagonist therapy
(all time periods versus during surgery) and age (all
ages versus children). To establish the robustness
of our results, we performed a sensitivity analysis in
which we excluded studies with high risk of bias be-
cause of incomplete outcome data. Given that our
primary analysis was a network meta-analysis restricted
to RCTs, we conducted a second sensitivity analysis in
which non-randomized studies were added to the net-
work, to observe the contribution of different study
designs to the treatment effects. Network meta-analyses
were conducted using the mvmeta command in Stata
13.0 [36, 37].Results
Literature search
After screening 7,608 citations, we reviewed 1,014 po-
tentially relevant full-text articles and identified 115 pri-
mary publications [10, 33, 38–150] and five companion
reports [151–154] (reporting on six studies) providing
data on 27,787 patients that met our inclusion criteria
(Fig. 1). Overall, 77 studies were excluded because they
reported results suspected or confirmed to be fraudulentases of the review; maps out the number of records identified,
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conference abstract [84].
Study and patient characteristics
The majority of the included studies were RCTs (97 %),
conducted in Europe (37 %), North America (26 %), or
Asia (24 %) and published between 1990 and 2013
(Table 1, Additional file 1: Appendix 2). The duration of
follow-up was very short, ranging from ≤6 h to more
than a week. The most frequent follow-up time observed
was 12 to 24 h (69 %). The setting was not reported in
the majority of trials (62 %) (Table 1).
The interventions examined were ondansetron (0.1−48
mg/day) (69 %), granisetron (0.1−3 mg/day) (12 %), tropi-
setron (0.3−5 mg/day) (13 %), dolasetron (12.5−200 mg/
day) (13 %), palonosetron (0.025−0.07 mg/day) (4 %), and
ramosetron (0.1−0.6 mg/day) (3 %). Some studies exam-
ined 5-HT3 receptor antagonists administered concomi-
tantly with other antiemetics, dexamethasone (2–16 mg/
day) (11 %) and droperidol (2.5 mg/day) (4 %), being the
most common (Table 1, Additional file 1: Appendix 3).
Arrhythmia was the most frequently reported outcome
(46 %). Only five studies reported QT prolongation, and
13 reported on the QT interval. None of the studies re-
ported the number of patients experiencing PR pro-
longation or sudden cardiac death. We abstracted data
from all of the included studies, and included 51 studies
in our analyses. Reasons for excluding studies from the
analyses included the manner in which the outcome was
reported (e.g., mean versus number of patients), report-
ing zero events for all treatment arms, and investigating
a single 5-HT3 receptor antagonist (with a different dos-
age in each treatment arm).
The average sample size was 242 participants ranging
from 28 to 1,044, and 64% of participants were women
(Table 2, Additional file 1: Appendix 4). Most of the
studies involved only adult patients (63 %), patients with
American Society of Anesthesiologists physical status I
or II (58 %), and patients who were undergoing obstet-
rical and gynecological (32 %) surgery. Patients’ history
of postoperative nausea and vomiting was reported in
58% of the studies, and history of motion sickness was
reported in 43 % of the studies. Comorbidities were
rarely reported (6 %) (Table 2).
Methodological quality and risk of bias
The majority of the included experimental and quasi-
experimental studies had unclear or high risk of bias on
the following items: allocation concealment (57 %), simi-
larity of baseline outcome characteristics (88 %), incom-
plete outcome data (51 %), selective outcome reporting
bias (97 %), and other types of bias, including the poten-
tial for funding bias because the study was funded by
private industry and an author on the publication wasemployed by the company sponsoring the study (88 %)
(Additional file 1: Appendix 5, 6). None of the 115 stud-
ies reporting harms outcomes fully reported all items on
the McHarm tool (Additional file 1: Appendix 7, 8).
The visual inspection of the comparison adjusted fun-
nel plots showed that there was no evidence for small-




The network meta-analysis for arrhythmia included 31
RCTs with 6,623 patients [40, 43, 45, 53, 59, 74, 78, 79,
83, 86–89, 97, 102, 108, 112–115, 117, 119, 123, 125,
128, 130, 132, 138, 141, 142, 150]. The network geom-
etry and included drugs can be found in Fig. 2a. Twenty-
one studies were excluded from the analysis because
they reported zero events in all arms [39, 43, 57, 60, 61,
71, 73, 81, 82, 86, 90, 92–94, 98, 110, 121, 127, 145, 155,
156]. Although the definitions of arrhythmia varied
across the studies (Additional file 1: Appendix 10), there
was no evidence of network inconsistency (χ2 = 3.49,
degrees of freedom = 10, P = 0.968, heterogeneity vari-
ance = 0.01), and the within-network heterogeneity vari-
ance was estimated to be 0.00. Among patients of all
ages receiving granisetron plus dexamethasone, signifi-
cantly more experienced arrhythmia compared with pla-
cebo (OR 2.96, 95 % CI 1.11–7.94), ondansetron (OR
3.23, 95 % CI 1.17–8.95), dolasetron (OR 4.37, 95 % CI
1.51–12.62), tropisetron (OR 3.27, 95 % CI 1.02–10.43),
and ondansetron plus dexamethasone (OR 5.75, 95 % CI
1.71–19.34) (Fig. 3, Table 3, Additional file 1: Appendix 11).
According to the SUCRA curves (Additional file 1:
Appendix 12), the safest agents for arrhythmia were
ondansetron plus dexamethasone (83 % probability) and
dolasetron (82 % probability).
A subgroup analysis was conducted for 26 RCTs in-
volving 4,878 patients in which the agents were admin-
istered during surgery [40, 43, 45, 53, 59, 74, 78, 79, 83,
86–89, 97, 102, 112, 113, 115, 117, 119, 123, 125, 132,
138, 142, 150]. The results were the same as for the pri-
mary analysis, except that significantly fewer patients of
all ages receiving dolasetron experienced arrhythmia com-
pared with placebo (OR 0.58, 95 % CI 0.36–0.93) and
ramosetron (OR 0.38, 95 % CI 0.17–0.92) (Additional
file 1: Appendix 13). According to the SUCRA curves
for this subgroup analysis, the safest agents were dola-
setron (86 % probability) and ondansetron plus dexa-
methasone (83 %).
Another subgroup analysis was conducted for nine RCTs
involving a total of 1,572 patients to examine the intra-
operative administration of ondansetron, ondansetron plus
dexamethasone, and granisetron plus dexamethasone
to children (Table 3, Additional file 1: Appendix 13)
Table 1 Study characteristics

















Not reported 1 0.9
South America 1 0.9
Study design
Randomized clinical trial 112 97.4








Not reported 98 85.2
Duration of follow-upb
0 to ≤6 9 7.8
>6 to ≤12 2 1.7
>12 to ≤24 79 68.7
>24 to ≤48 17 14.8
>48 to ≤72 2 1.7
>72 to ≤1 week 3 2.6
Not reported 3 2.6
Interventions examined:
frequencyc
Serotonin antagonists: Reported as administered alone (administered
with dexamethasone)
Ondansetron 79 (7) 68.70 (6.1)
Granisetron 14 (4) 12.2 (3.5)
Tropisetron 15 (0) 13.0 (0.0)
Dolasetron 15 (1) 13.0 (0.9)
Palonosetron 4 (0) 3.5 (0.0)
Ramosetron 3 (1) 2.6 (0.9)
































QT prolongation 18 15.7
Setting
Not reported 71 61.7
Hospital 25 21.7
Medical center 16 13.9
Multi-center 3 2.6
aIncludes unpublished data [84]; bduration is in hours unless otherwise noted;
cmultiple interventions and comparators examined across the studies;
dmultiple interventions and outcomes reported per study. NK-1: Neurokinin 1
receptor antagonist
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more children receiving granisetron plus dexametha-
sone during surgery experienced arrhythmia compared
with placebo (OR 5.15, 95 % CI 1.33–19.91), ondanse-
tron (OR 4.71, 95 % CI 1.08–20.46), and ondansetron
plus dexamethasone (OR 7.12, 95 % CI 1.66–30.63).
According to the SUCRA curves, the safest agent in
terms of arrhythmia was ondansetron plus dexametha-
sone (80 % probability). Finally, a sensitivity analysis
was conducted in which one RCT was removed be-
cause of high risk of incomplete outcome data [128],
and the same results were observed (Additional file 1:
Appendix 13).
Table 2 Patient characteristics
Total number of patients 27,787
Mean sample size 242






Children only (aged <18 years) 22 19.1
Adults only (aged ≥18 years to ≤65
years)
72 62.6
Children and adults (aged ≤65
years)
2 1.7
Adults and elderly (aged ≥18 years) 16 13.9
All ages 2 1.7





I or II 62 53.9
I or II or III 32 27.8
Not reported 17 14.8
Surgery type
Obstetric and gynecological 37 32.2
Eye 12 10.4
Gastrointestinal 9 7.8











surgery types, abdominal surgery,
and plastic surgery unspecified)
39 33.9
History of motion sickness
Yes 49 42.6
No or not reported 66 57.4
History of postoperative nausea
and vomiting
Yes 67 58.3
No or not reported 48 41.7
Comorbiditiesb
Not reported 109 94.8
Diabetes mellitus 3 2.6





Liver disease 1 0.9
aIncludes unpublished data; bsome studies considered more than
one comorbidity
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The network meta-analysis for delirium included 18
studies involving 3,652 patients in which ondansetron,
granisetron, dolasetron, tropisetron, and dolasetron plus
dexamethasone were administered during surgery [52,
60, 68, 69, 76, 79, 96, 100, 105, 106, 118, 124, 128, 133,
137, 139, 144, 146]. The network geometry and included
drugs can be found in Fig. 2b. Ten studies were excluded
from the analysis because they reported zero events in all
arms [49, 69, 75, 90, 99, 103, 129, 135, 140, 143]. No
statistically significant results were observed and the
within-network heterogeneity variance in the network
meta-analysis model was estimated to be 0.00 (Additional
file 1: Appendix 14). Although the definitions of delirium
varied across the studies (Additional file 1: Appendix 15,
16), there was no evidence of network inconsistency (χ2 =
0.32, degrees of freedom = 2, P = 0.851, heterogeneity
variance = 0.00).
Mortality
A meta-analysis was conducted for three studies includ-
ing 1,255 patients that reported mortality for compari-
sons of ondansetron with placebo [10, 111, 142]. No
statistically significant effects were observed (OR 1.92,
95 % CI 0.30–12.21). Twenty-five studies were excluded
from this analysis because they reported zero events in
both arms [38, 41, 44, 55, 56, 58, 62, 67, 70, 72, 77, 78,
80, 107, 109, 115, 120, 126, 128, 130, 131, 134, 149,
157, 158].
QT prolongation
Two RCTs reported the number of patients experiencing
QT prolongation [55, 116]. In one of these studies, there
was no statistically significant difference between ondan-
setron and placebo (OR 0.75, 95 % CI 0.47–1.20) [55],
and in the other there was no statistically significant dif-
ference between granisetron and placebo (OR 0.32, 95 %
CI 0.01–8.02) [116]. Three studies did not inform the
analysis and were excluded, as they reported zero events
in both arms [58, 115, 159].
Discussion
More patients receiving granisetron plus dexamethasone
experienced arrhythmia compared to other agents. The
Fig. 2 Network meta-analysis diagrams for (a) arrhythmia and (b) delirium. Nodes are proportional to the number of patients included in the
corresponding treatments, and edges are weighted according to the number of studies included in the respective comparisons. Dex: Dexamethasone;
Dolas: Dolasetron; Drop: Droperidol; Granis: Granisetron; Ondans: Ondansetron; Tropis: Tropisetron
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arrhythmia were ondansetron plus dexamethasone and
dolasetron for patients of all ages and ondansetron plus
dexamethasone for children (none of the included stud-
ies examined dolasetron in children). These results
were consistent across subgroup and sensitivity analyses.Fig. 3 Network meta-analysis results for arrhythmia. All treatments are compa
intervals (CI) of the summary treatment effects and red horizontal lines the 95
scale. Among patients of all ages receiving granisetron plus dexamethasone,
2.96, 95 % CI 1.11–7.94), ondansetron (OR 3.23, 95 % CI 1.17–8.95), dolasetron
and ondansetron plus dexamethasone (OR 5.75, 95 % CI 1.71–19.34). Note: Re
Predictive intervalNone of the agents caused significantly more patients to
experience delirium. Few studies reported QT prolonga-
tion, and no statistically significant results for this out-
come were reported in the two studies reporting at least
one event. As well, no statistically significant differences
in mortality were observed between ondansetron andred to placebo. The black horizontal lines represent the 95 % confidence
% predictive intervals (PrI). Results are presented on the odds ratio (OR)
significantly more experienced arrhythmia compared with placebo (OR
(OR 4.37, 95 % CI 1.51–12.62), tropisetron (OR 3.27, 95 % CI 1.02–10.43),
ference treatment is placebo. CI: Confidence interval; OR: Odds ratio; PrI:
Table 3 Statistically significant results of network meta-analysis for all time periods of drug administration
All ages Children only












Arrhythmia 31 RCTs and 6,623 patients 9 RCTs and 1,572 patients
Granisetron + DEX vs placebo 2 2.63 (0.75– 9.29) 2.96 (1.11–7.94) 1 4.89 (1.15–20.79) 5.15 (1.33–19.91)
Granisetron + DEX vs
ondansetron
NA NA 3.23 (1.17–8.95) NA NA 4.71 (1.08–20.46)
Granisetron + DEX vs
dolasetron
NA NA 4.37 (1.51–12.62) NA NA NA
Granisetron + DEX vs
tropisetron
NA NA 3.27 (1.02–10.43) NA NA NA
Granisetron + DEX vs
ondansetron + DEX
2 8.10 (1.92–34.13) 5.75 (1.71–19.34) 1 7.67 (1.47–40.00) 7.12 (1.66–30.63)
CI: Confidence interval; DEX: Dexamethasone; MA: Meta-analysis; NA: Not applicable; NMA: Network meta-analysis; OR: Odds ratio
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this outcome. None of the studies included in this ana-
lysis reported the number of patients experiencing PR
prolongation or sudden cardiac death.
Our finding of no increased risk of cardiac arrhythmia
in association with ondansetron therapy supports the re-
sults of a previous systematic review [160]. Although we
are aware of other systematic reviews and meta-analyses
of 5-HT3 receptor antagonists [9, 161], the previous re-
searchers did not conduct network meta-analysis, so we
cannot compare our results with theirs. Notably, because
of our comprehensive literature search and broad eligi-
bility criteria, we included 62 studies involving a total of
14,705 patients that were not included in any of the pre-
vious reviews (Additional file 1: Appendix 17).
We found no increased risk of arrhythmia with dolase-
tron for patients of any age. This does not mean that a
cardiac risk does not exist; we found no studies examin-
ing other cardiac harms, such as PR prolongation and
sudden cardiac death. We identified no studies examin-
ing dolasetron administered to children. We found other
data gaps through the conduct of this review. In particu-
lar, most of the studies focused on effectiveness out-
comes, and relatively few reported harms. Our network
meta-analysis results for the effectiveness outcomes have
been reported in another publication [8].
The studies included in our analysis had some methodo-
logical limitations. Most of the studies were small (average
sample size 242 patients) and larger sample sizes are re-
quired to assess harms, in particular harms that occur
only rarely, such as arrhythmia and delirium. Indeed, the
need for larger sample sizes is the reason we included
non-randomized studies in our review. Although these
non-randomized studies involved more patients than
the RCTs, their inclusion did not change the network
meta-analysis results obtained for arrhythmia or de-
lirium. As well, many of the studies failed to report
baseline characteristics or all items assessed by theMcHarm tool, and many of the included trials had an
unclear or high risk of bias on important items for the
conduct of trials, including allocation concealment,
selective outcome reporting bias, and potential for
funding bias.
Our systematic review process also had some limita-
tions. Slight changes to our original protocol [7] were
necessary, because of the enormous number of studies
that met our inclusion criteria. For example, we were
unable to report data on patients undergoing chemo-
therapy in this paper (but these will be disseminated in
an upcoming paper), we did not include studies written
in languages other than English, and we focused inclu-
sion to unpublished conference abstracts from the past
10 years that included relevant data. However, we were
able to include unpublished data from one study [84],
and our funnel plots showed no evidence of small-study
effects or publication bias. Furthermore, we assumed
that the effects of the different doses and durations were
identical across the treatments, and that they defined the
same node they belong to. We are currently exploring
these assumptions in another paper [162]. Finally, we
had to exclude 77 studies because they contained data
known or suspected to be fraudulent, as identified by ed-
itors and authors in the field and presented in a paper
[9]; we did not conduct a sensitivity analysis including
these articles to examine the effect of excluding these
studies on our results.
Conclusion
We conclude that most 5-HT3 receptor antagonists that
do not cause delirium. Granisetron plus dexamethasone
increased the risk of cardiac harm (arrhythmia), with the
number needed to harm ranging from five to eight. We
are unable to comment on the relationship between 5-
HT3 receptor antagonists and other cardiac harms, such
as for PR prolongation and sudden cardiac death, as no
studies reported these important outcomes.
Tricco et al. BMC Medicine  (2015) 13:142 Page 9 of 13Additional file
Additional file 1: Appendix 1–17. Includes 17 appendices with
supplementary data.Abbreviations
5-HT3: Serotonin; CI: Confidence interval; IV: Intravenous; NK-1: Neurokinin 1
receptor antagonist; NMA: Network meta-analysis; OR: Odds ratio;
PrI: Predictive interval; RCT: Randomized control trial; REML: Restricted
maximum likelihood; SUCRA: Surface under the cumulative ranking.
Competing interests
RR owns stock in a company (GlaxoSmithKline Inc) that manufactures one of
the interventions included in our study. All other authors declare that they
have no competing interests.
Authors’ contributions
ACT conceived the study, designed the study, helped obtain funding for
the study, guided the analysis, interpreted the results, and drafted the
manuscript. CS coordinated the review, screened citations and full-text
articles, abstracted data, appraised quality, cleaned the data, and edited the
manuscript. EB, LS, and HA screened citations and full-text articles, abstracted
data, appraised quality, cleaned the data, and edited the manuscript. AAV
analyzed the data, interpreted the data, wrote the synthesis section, and
edited the manuscript. PAK, AV, JI, HM, ER, RR, JH, CN, and KM screened
citations and full-text articles, appraised quality, and edited the manuscript.
JA provided methodological support and screened citations and full-text
articles. BH, BRH, and DM helped conceive the study and edited the manuscript.
SES conceived and designed the study, obtained the funding, interpreted the
results, and edited the manuscript. All authors read and approved the final
paper and agree to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
Acknowledgements
This systematic review was funded by the Canadian Institutes for Health
Research/Drug Safety and Effectiveness Network (CIHR/DSEN). ACT and BH
are funded by a CIHR/DSEN New Investigator Award in Knowledge Synthesis.
BRH receives funding from the Alberta Heritage Foundation for Medical
Research. AAV is funded by the Banting Postdoctoral Fellowship Program
from the CIHR. DM is funded by a University of Ottawa Research Chair. SES is
funded by a Tier 1 Canada Research Chair in Knowledge Translation. We
thank Laure Perrier for conducting the literature searches, Becky Skidmore for
peer-reviewing the literature search, and Drs Maggie Chen and Joseph
Beyene for providing feedback on conceptualization of the review. We also
thank Vladi Struchkov, Vera Nincic, Roberta Cardoso, Christy Johnson, and
Derek Roberts for screening some of the citations, and/or abstracting some
of the data, and/or appraising quality for a few of the included studies. Finally,
we thank Wing Hui for abstracting some of the data, Ana Guzman and Inthuja
Selvaratnam for formatting the manuscript, and Peggy Robinson for
copyediting the manuscript.
Author details
1Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 209 Victoria Street,
East Building, Toronto, ON M5B 1W8, Canada. 2Epidemiology Division, Dalla
Lana School of Public Health, University of Toronto, 6th floor, 155 College St,
Toronto, ON M5T 3M7, Canada. 3Institute for Health Policy Management and
Evaluation, University of Toronto, 4th Floor, 155 College St, Toronto, ON M5T
3M6, Canada. 4Departments of Community Health Sciences, Faculty of
Medicine, University of Calgary, TRW Building, 3rd Floor, 3280 Hospital Drive,
Calgary, AB T2N 4Z6, Canada. 5Clinical Epidemiology Program, Centre for
Practice-Changing Research, Ottawa Hospital Research Institute, 725 Parkdale
Ave, Ottawa, ON K1Y 4E9, Canada. 6Department of Geriatric Medicine,
University of Toronto, 27 King’s College Circle, Toronto, ON M5S 1A1,
Canada.
Received: 26 November 2014 Accepted: 19 May 2015References
1. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, et al. Consensus
guidelines for managing postoperative nausea and vomiting. Anesth Analg.
2003;97:62–71.
2. McCracken G, Houston P, Lefebvre G. Guideline for the management of
postoperative nausea and vomiting. J Obstet Gynaecol Can. 2008;30:600–7.
3. Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset
emesis. Ann Pharmacother. 2004;38:1683–91.
4. Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron
on electrocardiography in children receiving chemotherapy for acute
leukemia. Am J Clin Oncol. 2005;28:201–4.
5. Pinarli FG, Elli M, Dagdemir A, Baysal K, Acar S. Electrocardiographic findings
after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pediatr Blood Cancer. 2006;47:567–71.
6. Gagnon ML. Moving knowledge to action through dissemination and
exchange. J Clin Epidemiol. 2011;64:25–31.
7. Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al.
Safety of serotonin (5-HT3) receptor antagonists in patients undergoing
surgery and chemotherapy: protocol for a systematic review and network
meta-analysis. Syst Rev. 2013;2:46.
8. Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A et al.
Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients
undergoing surgery: a systematic review and network meta-analysis. BMC
Med. 2015; Ahead of print.
9. Carlisle JB. The analysis of 168 randomised controlled trials to test data
integrity. Anaesthesia. 2012;67:521–37.
10. Gan TJ, Gu J, Singla N, Chung F, Pearman MH, Bergese SD, et al. Rolapitant
for the prevention of postoperative nausea and vomiting: a prospective,
double-blinded, placebo-controlled randomized trial. Anesth Analg.
2011;112:804–12.
11. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. Ottawa: University of Ottawa; 2014.
12. Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D, et al.
Treatments for seasonal allergic rhinitis [Internet]. Rockville: Agency for
Healthcare Research and Quality; 2013. (Comparative Effectiveness Reviews,
No. 120.) Appendix F, McMaster Quality Assessment Scale of Harms
(McHarm). http://www.ncbi.nlm.nih.gov/books/NBK153703/. Accessed Jan
2015.
13. Raudenbush SW. Analyzing effect sizes: Random-effects models. In: Cooper
H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and
meta-analysis. 2nd ed. New York: The Russell Sage Foundation; 2009. p.
295–316.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat
Med. 2002;21:1539–58.
15. Viechtbauer W. Conducting meta-analyses in R with the metafor package.
J Stat Softw. 2010;36:1–48.
16. R Core Team. R: A language and environment for statistical computing.
http://www.R-project.org/. Accessed: Jan 2015.
17. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-
treatments meta-analysis: many names, many benefits, many concerns for
the next generation evidence synthesis tool. Res Synth Meth. 2012;3:80–97.
18. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools
for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
19. White IR, Barrett JK, Jackson D, Higgins J. Consistency and inconsistency in
network meta‐analysis: model estimation using multivariate meta‐regression.
Res Synth Meth. 2012;3:111–25.
20. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for
estimating efficacy of competing interventions: empirical evidence from
published meta-analyses. BMJ. 2003;326:472.
21. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency
in networks of interventions. Int J Epidemiol. 2013;42:332–45.
22. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical
summaries for presenting results from multiple-treatment meta-analysis: an
overview and tutorial. J Clin Epidemiol. 2011;64:163–71.
23. Chen CC, Lin CS, Ko YP, Hung YC, Lao HC, Hsu YW. Premedication with
mirtazapine reduces preoperative anxiety and postoperative nausea and
vomiting. Anesth Analg. 2008;106:109–13.
24. Omran HASA, Nasr DAM. Effect of premedication with mirtazapine versus
ondansetron on postoperative nausea and vomiting in breast surgery.
Egypt J Anaesth. 2011;27:135–9.
Tricco et al. BMC Medicine  (2015) 13:142 Page 10 of 1325. Homesley HD, Hahne WF, McLees B, Heck K, Barrett RJ, Lentz SS, et al.
Randomized comparison of the antiemetic efficacy of a serotonin type 3
receptor antagonist (MDL 72,222) with a high-dose metoclopramide
regimen. Am J Clin Oncol. 1993;16:175–9.
26. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, et al. Society for
Ambulatory Anesthesia guidelines for the management of postoperative
nausea and vomiting. Anesth Analg. 2007;105:1615–28.
27. Golembiewski J, Chernin E, Chopra T. Prevention and treatment of
postoperative nausea and vomiting. Am J Health Syst Pharm.
2005;62:1247–60.
28. Kovac AL. Prevention and treatment of postoperative nausea and vomiting.
Drugs. 2000;59:213–43.
29. Wilhelm SM, Dehoorne-Smith ML, Kale-Pradhan PB. Prevention of postoperative
nausea and vomiting. Ann Pharmacother. 2007;41(1):68–78. Epub 2007 Jan 2.
30. Yun MJ, Kim YH, Kim AR. Comparison of azasetron and ondansetron for
preventing postoperative nausea and vomiting in patients undergoing
gynecological laparoscopic surgery. Yonsei Med J. 2010;51:88–92.
31. Gunter JB, McAuliffe JJ, Beckman EC, Wittkugel EP, Spaeth JP, Varughese
AM. A factorial study of ondansetron, metoclopramide, and dexamethasone
for emesis prophylaxis after adenotonsillectomy in children. Paediatr
Anaesth. 2006;16:1153–65.
32. Gupta P, Khanna J, Mitramustafi AK, Bhartia VK. Role of pre-operative
dexamethasone as prophylaxis for postoperative nausea and vomiting in
laparoscopic surgery. J Minim Access Surg. 2006;2:12–5.
33. Gupta SD, Pal R, Sarkar A, Mukherjee S, Mitra K, Roy S, et al. Evaluation of
Ondansetron-induced QT interval prolongation in the prophylaxis of
postoperative emesis. J Nat Sci Biol Med. 2011;2:119–24.
34. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses.
BMJ. 2011;342:964–7.
35. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects
meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137–59.
36. White IR. Multivariate random-effects meta-regression: updates to mvmeta.
Stata J. 2011;11:255–70.
37. StataCorp. Stata Statistical Software: Release 13. College Station: StataCorp
LP; 2013.
38. Choi YS, Shim JK, Ahn SH, Kwak YL. Efficacy comparison of ramosetron with
ondansetron on preventing nausea and vomiting in high-risk patients
following spine surgery with a single bolus of dexamethasone as an
adjunct. Korean J Anesthesiol. 2012;62:543–7.
39. Wang PK, Tsay PJ, Huang CC, Lai HY, Lin PC, Huang SJ, et al. Comparison of
dexamethasone with ondansetron or haloperidol for prevention of patient-
controlled analgesia-related postoperative nausea and vomiting: a randomized
clinical trial. World J Surg. 2012;36:775–81.
40. Ekinci O, Malat I, Isitmangil G, Aydin N. A randomized comparison of
droperidol, metoclopramide, tropisetron, and ondansetron for the
prevention of postoperative nausea and vomiting. Gynecol Obstet Invest.
2011;71:59–65.
41. Park SK, Cho EJ. A randomized, double-blind trial of palonosetron compared
with ondansetron in preventing postoperative nausea and vomiting after
gynaecological laparoscopic surgery. J Int Med Res. 2011;39:399–407.
42. Ryu JH, Jeon YT, Hwang JW, Oh AY, Moon JY, Ro YJ, et al. Intravenous, oral,
and the combination of intravenous and oral ramosetron for the prevention
of nausea and vomiting after laparoscopic cholecystectomy: a randomized,
double-blind, controlled trial. Clin Ther. 2011;33:1162–72.
43. Sahoo T, SenDasgupta C, Goswami A, Hazra A. Reduction in spinal-induced
hypotension with ondansetron in parturients undergoing caesarean section:
a double-blind randomised, placebo-controlled study. Int J Obstet Anesth.
2012;21:24–8.
44. Bilgin TE, Birbicer H, Ozer Z, Doruk N, Tok E, Oral U. A comparative study of
the antiemetic efficacy of dexamethasone, ondansetron, and
metoclopramide in patients undergoing gynecological surgery. Med Sci
Monit. 2010;16:CR336–341.
45. Choi DK, Chin JH, Lee EH, Lim OB, Chung CH, Ro YJ, et al. Prophylactic
control of post-operative nausea and vomiting using ondansetron
and ramosetron after cardiac surgery. Acta Anaesthesiol Scand.
2010;54:962–9.
46. Jee YS, Yoon HJ, Jang CH. Prophylactic antiemetic effects in gynecologic
patients receiving fentanyl IV-patient controlled analgesia: comparison
of combined treatment with ondansetron and dexamethasone with
metoclopramide and dexamethasone. Korean J Anesthesiol.
2010;59:335–9.47. Jokela R, Ahonen J, Seitsonen E, Marjakangas P, Korttila K. The influence of
ondansetron on the analgesic effect of acetaminophen after laparoscopic
hysterectomy. Clin Pharmacol Ther. 2010;87:672–8.
48. Mehta D, Sanatani S, Whyte SD. The effects of droperidol and ondansetron
on dispersion of myocardial repolarization in children. Paediatr Anaesth.
2010;20:905–12.
49. Shakya S, Chaturvedi A, Sah BP. Prophylactic low dose ketamine and
ondansetron for prevention of shivering during spinal anaesthesia.
J Anaesthesiol Clin Pharmacol. 2010;26:465–9.
50. Singla NK, Singla SK, Chung F, Kutsogiannis DJ, Blackburn L, Lane SR, et al.
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1
receptor antagonist casopitant (GW679769) administered with ondansetron
for the prevention of postoperative and postdischarge nausea and vomiting
in high-risk patients. Anesthesiology. 2010;113:74–82.
51. Feng PH, Chu KS, Lu IC, Shieh JP, Tzeng JI, Ho ST, et al. Haloperidol plus
ondansetron prevents postoperative nausea and vomiting in patients
undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan.
2009;47:3–9.
52. Jain V, Mitra JK, Rath GP, Prabhakar H, Bithal PK, Dash HH. A randomized,
double-blinded comparison of ondansetron, granisetron, and placebo for
prevention of postoperative nausea and vomiting after supratentorial
craniotomy. J Neurosurg Anesthesiol. 2009;21:226–30.
53. Riad W, Marouf H. Combination therapy in the prevention of PONV after
strabismus surgery in children: granisetron, ondansetron, midazolam with
dexamethasone. Middle East J Anesthesiol. 2009;20:431–6.
54. Rosow CE, Haspel KL, Smith SE, Grecu L, Bittner EA. Haloperidol versus
ondansetron for prophylaxis of postoperative nausea and vomiting. Anesth
Analg. 2008;106:1407–9. table of contents.
55. Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T. Palonosetron
04–06 Study G. A randomized, double-blind study to evaluate the efficacy
and safety of three different doses of palonosetron versus placebo for
preventing postoperative nausea and vomiting. Anesth Analg.
2008;107:445–51.
56. Choi YS, Shim JK, Yoon do H, Jeon DH, Lee JY, Kwak YL. Effect of ramosetron
on patient-controlled analgesia related nausea and vomiting after spine
surgery in highly susceptible patients: comparison with ondansetron. Spine
(Phila Pa 1976). 2008;33:E602–6.
57. Contreras-Dominguez V, Carbonell-Bellolio P. Prophylactic antiemetic
therapy for acute abdominal surgery. A comparative study of droperidol,
metoclopramide, tropisetron, granisetron and dexamethasone. Rev Bras
Anestesiol. 2008;58:35–44.
58. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. Palonosetron 04–07 Study
G. A randomized, double-blind study to evaluate the efficacy and safety
of three different doses of palonosetron versus placebo in preventing
postoperative nausea and vomiting over a 72-hour period. Anesth Analg.
2008;107:439–44.
59. Owczuk R, Wenski W, Polak-Krzeminska A, Twardowski P, Arszulowicz R,
Dylczyk-Sommer A, et al. Ondansetron given intravenously attenuates
arterial blood pressure drop due to spinal anesthesia: a double-blind,
placebo-controlled study. Reg Anesth Pain Med. 2008;33:332–9.
60. Piper SN, Rohm K, Boldt J, Kranke P, Maleck W, Seifert R, et al. Postoperative
nausea and vomiting after surgery for prognathism: not only a question of
patients’ comfort. A placebo-controlled comparison of dolasetron and
droperidol. J Craniomaxillofac Surg. 2008;36:173–9.
61. Said-Ahmed HAF. Does granisetron affect the analgesic efficacy of tramadol
in patients undergoing abdominal hysterectomy? Acta Anaesthesiologica
Italica. 2008;59:256–66.
62. Bestas A, Önal SA, Bayar MK, Yildirim A, Aygen E. Effects of ondansetron and
granisetron on postoperative nausea and vomiting in adult patients
undergoing laparoscopic cholecystectomy: a randomized, double-blind,
placebo-controlled clinical trial. Curr Ther Res Clin Exp. 2007;68:303–12.
63. Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, et al.
Single-dose aprepitant vs ondansetron for the prevention of postoperative
nausea and vomiting: a randomized, double-blind phase III trial in patients
undergoing open abdominal surgery. Br J Anaesth. 2007;99:202–11.
64. Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A
randomized, double-blind comparison of the NK1 antagonist, aprepitant,
versus ondansetron for the prevention of postoperative nausea and vomiting.
Anesth Analg. 2007;104:1082–9. tables of contents.
65. Han DW, Hong SW, Kwon JY, Lee JW, Kim KJ. Epidural ondansetron is more
effective to prevent postoperative pruritus and nausea than intravenous
Tricco et al. BMC Medicine  (2015) 13:142 Page 11 of 13ondansetron in elective cesarean delivery. Acta Obstet Gynecol Scand.
2007;86:683–7.
66. Lee Y, Wang PK, Lai HY, Yang YL, Chu CC, Wang JJ. Haloperidol is as
effective as ondansetron for preventing postoperative nausea and vomiting.
Can J Anaesth. 2007;54:349–54.
67. Oksuz H, Zencirci B, Ezberci M. Comparison of the effectiveness of
metoclopramide, ondansetron, and granisetron on the prevention of
nausea and vomiting after laparoscopic cholecystectomy. J Laparoendosc
Adv Surg Tech A. 2007;17:803–8.
68. Rusch D, Arndt C, Martin H, Kranke P. The addition of dexamethasone to
dolasetron or haloperidol for treatment of established postoperative nausea
and vomiting. Anaesthesia. 2007;62:810–7.
69. Sagir O, Gulhas N, Toprak H, Yucel A, Begec Z, Ersoy O. Control of shivering
during regional anaesthesia: prophylactic ketamine and granisetron. Acta
Anaesthesiol Scand. 2007;51:44–9.
70. Sandhu T, Tanvatcharaphan P, Cheunjongkolkul V. Ondansetron versus
metoclopramide in prophylaxis of nausea and vomiting for laparoscopic
cholecystectomy: a prospective double-blind randomized study. Asian J
Surg. 2008;31:50–4.
71. Siddik-Sayyid SM, Aouad MT, Taha SK, Azar MS, Hakki MA, Kaddoum RN,
et al. Does ondansetron or granisetron prevent subarachnoid morphine-
induced pruritus after cesarean delivery? Anesth Analg. 2007;104:421–4.
72. Bridges JD, Nettle CB, Dugirrala VJ, Suda KJ, Garey KW. Low-dose granisetron
for the prevention of postoperative nausea and vomiting. J Appl Res.
2006;6:223–9.
73. Chan MT, Choi KC, Gin T, Chui PT, Short TG, Yuen PM, et al. The additive
interactions between ondansetron and droperidol for preventing
postoperative nausea and vomiting. Anesth Analg. 2006;103:1155–62.
74. Kelsaka E, Baris S, Karakaya D, Sarihasan B. Comparison of ondansetron and
meperidine for prevention of shivering in patients undergoing spinal
anesthesia. Reg Anesth Pain Med. 2006;31:40–5.
75. Sarvela PJ, Halonen PM, Soikkeli AI, Kainu JP, Korttila KT. Ondansetron and
tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus
in elective cesarean delivery. Acta Anaesthesiol Scand. 2006;50:239–44.
76. Tosun Z, Akin A, Dogan H, Boyaci A. A randomized, placebo-controlled trial
of a single dose of tropisetron for the prevention of vomiting after strabismus
surgery in children. Mt Sinai J Med. 2006;73:1106–11.
77. D’Angelo R, Philip B, Gan TJ, Kovac A, Hantler C, Doblar D, et al. A randomized,
double-blind, close-ranging, pilot study of intravenous granisetron in the
prevention of postoperative nausea and vomiting in patients abdominal
hysterectomy. Eur J Anaesthesiol. 2005;22:774–9.
78. Gan TJ, Coop A, Philip BK. A randomized, double-blind study of granisetron
plus dexamethasone versus ondansetron plus dexamethasone to prevent
postoperative nausea and vomiting in patients undergoing abdominal
hysterectomy. Anesth Analg. 2005;101:1323–9.
79. Khalil SN, Roth AG, Cohen IT, Simhi E, Ansermino JM, Bolos ME, et al. A
double-blind comparison of intravenous ondansetron and placebo for
preventing postoperative emesis in 1- to 24-month-old pediatric patients
after surgery under general anesthesia. Anesth Analg. 2005;101:356–61. table
of contents.
80. Kocamanoglu IS, Baris S, Karakaya D, Sener B, Tur A, Cetinkaya M. Effects of
granisetron with droperidol or dexamethasone on prevention of
postoperative nausea and vomiting after general anesthesia for cesarean
section. Methods Find Exp Clin Pharmacol. 2005;27:489–93.
81. Kontrimaviciute E, Baublys A, Ivaskevicius J. Postoperative nausea and
vomiting in patients undergoing total abdominal hysterectomy under
spinal anaesthesia: a randomized study of ondansetron prophylaxis. Eur J
Anaesthesiol. 2005;22:504–9.
82. Pirat A, Tuncay SF, Torgay A, Candan S, Arslan G. Ondansetron, orally
disintegrating tablets versus intravenous injection for prevention of
intrathecal morphine-induced nausea, vomiting, and pruritus in young
males. Anesth Analg. 2005;101:1330–6.
83. Treschan TA, Zimmer C, Nass C, Stegen B, Esser J, Peters J. Inspired oxygen
fraction of 0.8 does not attenuate postoperative nausea and vomiting after
strabismus surgery. Anesthesiology. 2005;103:6–10.
84. White PF, Scuderi PE. Prevention of postoperative nausea and vomiting
(PONV): A dose-ranging study involving palonosetron, a potent 5-HT3
receptor antagonist. Anesthesiology. 2005;103:A703.
85. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial
trial of six interventions for the prevention of postoperative nausea and
vomiting. N Engl J Med. 2004;350:2441–51.86. Binstock W, Rubin R, Bachman C, Kahana M, McDade W, Lynch JP. The
effect of premedication with OTFC, with or without ondansetron, on
postoperative agitation, and nausea and vomiting in pediatric ambulatory
patients. Paediatr Anaesth. 2004;14:759–67.
87. Eberhart LH, Morin AM, Hoerle S, Wulf H, Geldner G. Droperidol and
dolasetron alone or in combination for prevention of postoperative nausea
and vomiting after vitrectomy. Ophthalmology. 2004;111:1569–75.
88. Hanaoka K, Toyooka H, Kugimiya T, Ohashi Y. Granisetron Study Group of
Japan. Efficacy of prophylactic intravenous granisetron in postoperative
emesis in adults. J Anesth. 2004;18:158–65.
89. Samarkandi AH, Riad W, Altaf R, Fatani R. Dexamethasone-ondansetron
combination in prevention of nausea and vomiting after strabismus surgery
in children. Egypt J Anaesth. 2004;20:399–403.
90. Charuluxananan S, Kyokong O, Somboonviboon W, Narasethakamol A,
Promlok P. Nalbuphine versus ondansetron for prevention of intrathecal
morphine-induced pruritus after cesarean delivery. Anesth Analg.
2003;96:1789–93. table of contents.
91. Loewen P, Lamb S, Clugston P. Randomized, double-blind trial of dolasetron
versus droperidol for prophylaxis of postoperative nausea and vomiting in
patients undergoing TRAM flap breast reconstruction surgery. Ann Plast
Surg. 2003;51:472–7.
92. O’Brien CM, Titley G, Whitehurst P. A comparison of cyclizine, ondansetron
and placebo as prophylaxis against postoperative nausea and vomiting in
children. Anaesthesia. 2003;58:707–11.
93. Argiriadou H, Papaziogas B, Pavlidis T, Parlapani A, Georgiou M,
Papagiannopoulou P, et al. Tropisetron vs ondansetron for prevention of
postoperative nausea and vomiting after laparoscopic cholecystectomy: a
randomized double-blind, placebo-controlled study. Surg Endosc.
2002;16:1087–90.
94. Gurkan Y, Toker K. Prophylactic ondansetron reduces the incidence of intrathecal
fentanyl-induced pruritus. Anesth Analg. 2002;95:1763–6. table of contents.
95. Dabbous A, Khoury SJ, Chehab IR, Bartelmaos T, Khoury G. Ondansetron
versus dehydrobenzoperidol and metoclopramide for management of
postoperative nausea in laparoscopic surgery patients. JSLS. 2001;5:139–42.
96. Kathirvel S, Dash HH, Bhatia A, Subramaniam B, Prakash A, Shenoy S. Effect
of prophylactic ondansetron on postoperative nausea and vomiting after
elective craniotomy. J Neurosurg Anesthesiol. 2001;13:207–12.
97. Subramaniam B, Madan R, Sadhasivam S, Sennaraj B, Tamilselvan P,
Rajeshwari S, et al. Dexamethasone is a cost-effective alternative to
ondansetron in preventing PONV after paediatric strabismus repair. Br J
Anaesth. 2001;86:84–9.
98. Ahmed AB, Hobbs GJ, Curran JP. Randomized, placebo-controlled trial of
combination antiemetic prophylaxis for day-case gynaecological laparoscopic
surgery. Br J Anaesth. 2000;85:678–82.
99. Charuluxananan S, Somboonviboon W, Kyokong O, Nimcharoendee K.
Ondansetron for treatment of intrathecal morphine-induced pruritus after
cesarean delivery. Reg Anesth Pain Med. 2000;25:535–9.
100. Jensen AB, Christiansen DB, Coulthard K, Wilkins A, Roberts G, Walt JH, et al.
Tropisetron reduces postoperative vomiting in children undergoing
tonsillectomy. Paediatr Anaesth. 2000;10:69–75.
101. Kreisler NS, Spiekermann BF, Ascari CM, Rhyne HA, Kloth RL, Sullivan LM,
et al. Small-dose droperidol effectively reduces nausea in a general surgical
adult patient population. Anesth Analg. 2000;91:1256–61.
102. Philip BK, Pearman MH, Kovac AL, Chelly JE, Wetchler BV, McKenzie R, et al.
Dolasetron for the prevention of postoperative nausea and vomiting
following outpatient surgery with general anaesthesia: a randomized,
placebo-controlled study. The Dolasetron PONV Prevention Study Group.
Eur J Anaesthesiol. 2000;17:23–32.
103. Zarate E, Watcha MF, White PF, Klein KW, Sa Rego M, Stewart DG. A
comparison of the costs and efficacy of ondansetron versus dolasetron for
antiemetic prophylaxis. Anesth Analg. 2000;90:1352–8.
104. Koivuranta M, Ala-Kokko TI, Jokela R, Ranta P. Comparison of ondansetron
and tropisetron combined with droperidol for the prevention of emesis
in women with a history of post-operative nausea and vomiting. Eur J
Anaesthesiol. 1999;16:390–5.
105. McCall JE, Stubbs K, Saylors S, Pohlman S, Ivers B, Smith S, et al. The search
for cost-effective prevention of postoperative nausea and vomiting in the child
undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate.
J Burn Care Rehabil. 1999;20:309–15.
106. Sinha PK, Tripathi M, Ambesh SP. Efficacy of ondansetron in prophylaxis of
postoperative nausea and vomiting in patients following infratentorial
Tricco et al. BMC Medicine  (2015) 13:142 Page 12 of 13surgery: a placebo-controlled prospective double-blind study. J Neurosurg
Anesthesiol. 1999;11:6–10.
107. Tsui SL, Ng KF, Wong LC, Tang GW, Pun TC, Yang JC. Prevention of postoperative
nausea and vomiting in gynaecological laparotomies: a comparison of
tropisetron and ondansetron. Anaesth Intensive Care. 1999;27:471–6.
108. Diemunsch P, Korttila K, Leeser J, Helmers JH, Wilkey B, Nave S, et al. Oral
dolasetron mesylate for prevention of postoperative nausea and vomiting:
a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron
PONV Prevention Study Group. J Clin Anesth. 1998;10:145–52.
109. Goodarzi M. A double blind comparison of droperidol and ondansetron for
prevention of emesis in children undergoing orthopaedic surgery. Paediatr
Anaesth. 1998;8:325–9.
110. Hamid SK, Selby IR, Sikich N, Lerman J. Vomiting after adenotonsillectomy in
children: a comparison of ondansetron, dimenhydrinate, and placebo.
Anesth Analg. 1998;86:496–500.
111. Morris RW, Aune H, Feiss P, Hanson A, Hasselstrom L, Maltby JR, et al.
International, multicentre, placebo-controlled study to evaluate the
effectiveness of ondansetron vs. metoclopramide in the prevention of
post-operative nausea and vomiting. Eur J Anaesthesiol. 1998;15:69–79.
112. Scholz J, Hennes HJ, Steinfath M, Farber L, Schweiger C, Dick W, et al.
Tropisetron or ondansetron compared with placebo for prevention of
postoperative nausea and vomiting. Eur J Anaesthesiol. 1998;15:676–85.
113. Tramer MR, Sansonetti A, Fuchs-Buder T, Rifat K. Oculocardiac reflex and
postoperative vomiting in paediatric strabismus surgery. A randomised
controlled trial comparing four anaesthetic techniques. Acta Anaesthesiol
Scand. 1998;42:117–23.
114. Diemunsch P, D’Hollander A, Paxton L, Schoeffler P, Wessel P, Nave S, et al.
Intravenous dolasetron mesilate in the prevention of postoperative nausea
and vomiting in females undergoing gynecological surgery. J Clin Anesth.
1997;9:365–73.
115. Diemunsch P, Leeser J, Feiss P, D’Hollander A, Bradburn BG, Paxton D, et al.
Intravenous dolasetron mesilate ameliorates postoperative nausea and
vomiting. Can J Anaesth. 1997;44:173–81.
116. Graczyk SG, McKenzie R, Kallar S, Hickok CB, Melson T, Morrill B, et al.
Intravenous dolasetron for the prevention of postoperative nausea and
vomiting after outpatient laparoscopic gynecologic surgery. Anesth Analg.
1997;84:325–30.
117. Klockgether-Radke A, Neumann S, Neumann P, Braun U, Muhlendyck H.
Ondansetron, droperidol and their combination for the prevention of
post-operative vomiting in children. Eur J Anaesthesiol. 1997;14:362–7.
118. Koivuranta M, Laara E, Ranta P, Ravaska P, Alahuhta S. Comparison of
ondansetron and droperidol in the prevention of postoperative nausea and
vomiting after laparoscopic surgery in women. A randomised, double-blind,
placebo-controlled trial. Acta Anaesthesiol Scand. 1997;41:1273–9.
119. Korttila K, Clergue F, Leeser J, Feiss P, Olthoff D, Payeur-Michel C, et al.
Intravenous dolasetron and ondansetron in prevention of postoperative
nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Acta Anaesthesiol Scand. 1997;41:914–22.
120. Kovac AL, Scuderi PE, Boerner TF, Chelly JE, Goldberg ME, Hantler CB, et al.
Treatment of postoperative nausea and vomiting with single intravenous
doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV
Treatment Study Group. Anesth Analg. 1997;85:546–52.
121. Mikawa K, Takao Y, Nishina K, Shiga M, Maekawa N, Obara H. Optimal dose
of granisetron for prophylaxis against postoperative emesis after
gynecological surgery. Anesth Analg. 1997;85:652–6.
122. Monagle J, Barnes R, Goodchild C, Hewitt M. Ondansetron is not superior to
moderate dose metoclopramide in the prevention of post-operative nausea
and vomiting after minor gynaecological surgery. Eur J Anaesthesiol.
1997;14:604–9.
123. Morton NS, Camu F, Dorman T, Knudsen KE, Kvalsvik O, Nellgard P, et al.
Ondansetron reduces nausea and vomiting after paediatric
adenotonsillectomy. Paediatr Anaesth. 1997;7:37–45.
124. Patel RI, Davis PJ, Orr RJ, Ferrari LR, Rimar S, Hannallah RS, et al. Single-dose
ondansetron prevents postoperative vomiting in pediatric outpatients.
Anesth Analg. 1997;85:538–45.
125. Purhonen S, Kauko M, Koski EM, Nuutinen L. Comparison of tropisetron,
droperidol, and saline in the prevention of postoperative nausea and
vomiting after gynecologic surgery. Anesth Analg. 1997;84:662–7.
126. Rung GW, Claybon L, Hord A, Patel C, Kallgren M, Koppel J, et al. Intravenous
ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255
Study Group. Anesth Analg. 1997;84:832–8.127. Scuderi PE, Weaver Jr RG, James RL, Mims G, Elliott WG, Weeks DB. A
randomized, double-blind, placebo controlled comparison of droperidol,
ondansetron, and metoclopramide for the prevention of vomiting following
outpatient strabismus surgery in children. J Clin Anesth. 1997;9:551–8.
128. Taylor AM, Rosen M, Diemunsch PA, Thorin D, Houweling PL. A double-
blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of
intravenous granisetron in the treatment of postoperative nausea and
vomiting in patients undergoing surgery with general anesthesia. J Clin
Anesth. 1997;9:658–63.
129. Ulusoy HO, Akturk G, Luleci N, Kalac N, Albayrak D. Prophylactic
administration of ondansetron in emergency intraabdominal operations.
Middle East J Anesthesiol. 1997;14:45–58.
130. Warriner CB, Knox D, Belo S, Cole C, Finegan BA, Perreault L. Prophylactic
oral dolasetron mesylate reduces nausea and vomiting after abdominal
hysterectomy. The Canadian Dolasetron Study Group. Can J Anaesth.
1997;44:1167–73.
131. Ali-Melkkila T, Kanto J, Katevuo R. Tropisetron and metoclopramide in the
prevention of postoperative nausea and vomiting. A comparative, placebo
controlled study in patients undergoing ophthalmic surgery. Anaesthesia.
1996;51:232–5.
132. Capouet V, De Pauw C, Vernet B, Ivens D, Derijcke V, Versichelen L, et al.
Single dose i.v. tropisetron in the prevention of postoperative nausea and
vomiting after gynaecological surgery. Br J Anaesth. 1996;76:54–60.
133. Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, et al.
Ondansetron prevents postoperative emesis in male outpatients. S3A-379
Study Group. J Clin Anesth. 1996;8:644–51.
134. Naguib M, el Bakry AK, Khoshim MH, Channa AB, el Gammal M, el Gammal
K, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron,
granisetron and metoclopramide in patients undergoing laparoscopic
cholecystectomy: a randomized, double-blind comparison with placebo.
Can J Anaesth. 1996;43:226–31.
135. Desilva PH, Darvish AH, McDonald SM, Cronin MK, Clark K. The efficacy of
prophylactic ondansetron, droperidol, perphenazine, and metoclopramide
in the prevention of nausea and vomiting after major gynecologic surgery.
Anesth Analg. 1995;81:139–43.
136. Litman RS, Wu CL, Lee A, Griswold JD, Voisine R, Marshall C. Prevention of
emesis after strabismus repair in children: a prospective, double-blinded,
randomized comparison of droperidol versus ondansetron. J Clin Anesth.
1995;7:58–62.
137. Paech MJ, Pavy TJ, Evans SF. Single-dose prophylaxis for postoperative
nausea and vomiting after major abdominal surgery: ondansetron versus
droperidol. Anaesth Intensive Care. 1995;23:548–54.
138. Paxton D, Taylor RH, Gallagher TM, Crean PM. Postoperative emesis
following otoplasty in children. Anaesthesia. 1995;50:1083–5.
139. Kaufmann MA, Rosow C, Schnieper P, Schneider M. Prophylactic antiemetic
therapy with patient-controlled analgesia: a double-blind, placebo-
controlled comparison of droperidol, metoclopramide, and tropisetron.
Anesth Analg. 1994;78:988–94.
140. Ummenhofer W, Frei FJ, Urwyler A, Kern C, Drewe J. Effects of ondansetron
in the prevention of postoperative nausea and vomiting in children.
Anesthesiology. 1994;81:804–10.
141. Dupeyron JP, Conseiller C, Levarlet M, Hemmingsen C, Schoeffler P,
Pedersen FM, et al. The effect of oral ondansetron in the prevention of
postoperative nausea and vomiting after major gynaecological surgery
performed under general anaesthesia. Anaesthesia. 1993;48:214–8.
142. Helmers JH, Briggs L, Abrahamsson J, Soni J, Moodley J, Forrler M, et al.
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia
reduces postoperative nausea and vomiting in gynaecological patients.
Can J Anaesth. 1993;40:1155–61.
143. Raphael JH, Norton AC. Antiemetic efficacy of prophylactic ondansetron
in laparoscopic surgery: randomized, double-blind comparison with
metoclopramide. Br J Anaesth. 1993;71:845–8.
144. Du Pen S, Scuderi P, Wetchler B, Sung YF, Mingus M, Clayborn L, et al.
Ondansetron in the treatment of postoperative nausea and vomiting in
ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Eur J Anaesthesiol Suppl. 1992;6:55–62.
145. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J.
Prolongation of QTc interval after postoperative nausea and vomiting
treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094–100.
146. Kovac A, McKenzie R, O’Connor T, Duncalf D, Angel J, Gratz I, et al.
Prophylactic intravenous ondansetron in female outpatients undergoing
Tricco et al. BMC Medicine  (2015) 13:142 Page 13 of 13gynaecological surgery: a multicentre dose-comparison study. Eur J
Anaesthesiol Suppl. 1992;6:37–47.
147. Lerman J, Sims C, Sikich N, Gow R, Chin C, Dempsey E, et al.
Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron
mesylate after oral or intravenous administration to anesthetized children.
Clin Pharmacol Ther. 1996;60:485–92.
148. Wagner DS, Gauger V, Chiravuri D, Faust K. Ondansetron oral disintegrating
tablets for the prevention of postoperative vomiting in children undergoing
strabismus surgery. Ther Clin Risk Manag. 2007;3:691–4.
149. Rose JB, Brenn BR, Corddry DH, Thomas PC. Preoperative oral ondansetron
for pediatric tonsillectomy. Anesth Analg. 1996;82:558–62.
150. El-Deeb A, Abd el motlb E. Prophylactic multimodal antiemetic in women
undergoing cesarean section under spinal anesthesia. Egypt J Anaesth.
2011;27:107–11.
151. Jokela RM, Cakmakkaya OS, Danzeisen O, Korttila KT, Kranke P, Malhotra A,
et al. Ondansetron has similar clinical efficacy against both nausea and
vomiting. Anaesthesia. 2009;64:147–51.
152. Pearman MH. Single dose intravenous ondansetron in the prevention of
postoperative nausea and vomiting. Anaesthesia. 1994;49:11–5.
153. Scuderi P, Wetchler B, Sung YF, Mingus M, DuPen S, Claybon L, et al.
Treatment of postoperative nausea and vomiting after outpatient surgery
with the 5-HT3 antagonist ondansetron. Anesthesiology. 1993;78:15–20.
154. McKenzie R, Kovac A, O’Connor T, Duncalf D, Angel J, Gratz I, et al.
Comparison of ondansetron versus placebo to prevent postoperative
nausea and vomiting in women undergoing ambulatory gynecologic
surgery. Anesthesiology. 1993;78:21–8.
155. Bagameri A, Bosze P. Ondansetron (Zofran) treatment of chemotherapy
induced nausea and vomiting in patients with gynecological malignancies.
Magy Noorv Lapja. 1994;57:291–3.
156. Chen LK, Fan SZ, Huang CH, Chao A, Cherng YG, Chen CL, et al. Effects of
ondansetron on postoperative emesis in Chinese children. Acta
Anaesthesiol Sin. 1998;36:87–91.
157. Ebrahim Soltani AR, Mohammadinasab H, Goudarzi M, Arbabi S,
Mohammadinasab A, Mohammadinasab F, et al. Comparing the efficacy of
prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in
the prevention of vomiting and nausea after strabismus surgery. Acta Med
Iran. 2011;49:208–12.
158. Ng WW, Li AC, Lee DW, Leung TL, Ko CW, Leung KF, et al. Effectiveness of
Ondansetron to prevent postoperative nausea and vomiting in ambulatory
two port needlescopic cholecystectomy: a randomised controlled trial.
Ambul Surg. 2008;14:1–14.
159. Aouad MT, Siddik-Sayyid SM, Taha SK, Azar MS, Nasr VG, Hakki MA, et al.
Haloperidol vs. ondansetron for the prevention of postoperative nausea and
vomiting following gynaecological surgery. Eur J Anaesthesiol. 2007;24:171–8.
160. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk
of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann
Emerg Med. 2014;64:19–25.
161. Rawlinson A, Kitchingham N, Hart C, McMahon G, Ong SL, Khanna A.
Mechanisms of reducing postoperative pain, nausea and vomiting: a
systematic review of current techniques. Evid Based Med. 2012;17:75–80.
162. Tricco A, Veroniki A, Blondal E, Hamid J, Straus S. Incorporating dosages
increases the relevance of network meta-analysis for decision-makers: A case
example using data from a systematic review of serotonin (5-HT3) receptor
antagonists in patients undergoing surgery. Toronto: Canadian Association
of Pharmacy Technicians (CAPT) Conference; 2014.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
